Generic Contrave Availability

Last updated on Apr 10, 2025.

Contrave is a brand name of bupropion/naltrexone, approved by the FDA in the following formulation(s):

CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride - tablet, extended release;oral)

Manufacturer: NALPROPION
Approval date: September 10, 2014
Strength(s): 90MG;8MG ^[RLD]

Is there a generic version of Contrave available?

No. There is currently no therapeutically equivalent version of Contrave available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Contrave. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions and methods for weight loss in at risk patient populations
Patent 10,231,964
Issued: March 19, 2019
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Nalpropion Pharmaceuticals, Inc.
The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
Patent expiration dates:
- July 2, 2034
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods for administering weight loss medications
Patent 10,307,376
Issued: June 4, 2019
Inventor(s): McKinney Anthony A. & Tollefson Gary & Weber Eckard & Soltero Rick
Assignee(s): Nalpropion Pharmaceuticals, Inc.
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
Patent expiration dates:
- November 8, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
Methods of treating overweight and obesity
Patent 10,403,170
Issued: September 3, 2019
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Nalpropion Pharmaceuticals, Inc.
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Patent expiration dates:
- June 5, 2033
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Compositions and methods for weight loss in at risk patient populations
Patent 10,828,294
Issued: November 10, 2020
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Nalpropion Pharmaceuticals LLC
The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
Patent expiration dates:
- July 2, 2034
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Compositions and methods for reducing major adverse cardiovascular events
Patent 10,835,527
Issued: November 17, 2020
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Nalpropion Pharmaceuticals LLC
The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.
Patent expiration dates:
- July 2, 2034
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods of providing weight loss therapy in patients with major depression
Patent 11,033,543
Issued: June 15, 2021
Inventor(s): Dunayevich Eduardo & Tollefson Gary
Assignee(s): Nalpropion Pharmaceuticals LLC
Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
Patent expiration dates:
- January 10, 2031
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods of treating overweight and obesity
Patent 11,139,056
Issued: October 5, 2021
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Nalpropion Pharmaceuticals LLC
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Patent expiration dates:
- June 5, 2033
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods for treating visceral fat conditions
Patent 11,324,741
Issued: May 10, 2022
Inventor(s): Tollefson; Gary D.
Assignee(s): Nalpropion Pharmaceuticals LLC (Morristown, NJ)
Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
Patent expiration dates:
- May 29, 2029
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Compositions and methods for reducing major adverse cardiovascular events
Patent 11,998,542
Issued: June 4, 2024
Inventor(s): Klassen; Preston et al.
Assignee(s): Nalpropion Pharmaceuticals LLC (Brentwood, TN)
The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE.
Patent expiration dates:
- July 2, 2034
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods for administering weight loss medications
Patent 12,048,769
Issued: July 30, 2024
Inventor(s): McKinney; Anthony A et al.
Assignee(s): Nalpropion Pharmaceuticals LLC (Brentwood, TN)
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
Patent expiration dates:
- November 8, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
Compositions for affecting weight loss
Patent 7,375,111
Issued: May 20, 2008
Inventor(s): Weber; Eckard et al.
Assignee(s): Orexigen Therapeutics, Inc. (San Diego, CA)
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Patent expiration dates:
- March 26, 2025
  ✓
  Drug product
Layered pharmaceutical formulations
Patent 8,088,786
Issued: January 3, 2012
Inventor(s): McKinney Anthony & Tollefson Gary & Weber Eckard & Soltero Rick
Assignee(s): Orexigen Therapeutics, Inc.
In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
Patent expiration dates:
- February 3, 2029
  ✓
  Drug product
Layered pharmaceutical formulations
Patent 8,318,788
Issued: November 27, 2012
Inventor(s): McKinney Anthony & Tollefson Gary & Weber Eckard & Soltero Rick
Assignee(s): Orexigen Therapeutics, Inc.
In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
Patent expiration dates:
- November 8, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
Methods for administering weight loss medications
Patent 8,722,085
Issued: May 13, 2014
Inventor(s): McKinney Anthony & Tollefson Gary & Weber Eckard & Soltero Rick
Assignee(s): Orexigen Therapeutics, Inc.
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
Patent expiration dates:
- November 8, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
Sustained release formulation of naltrexone
Patent 8,916,195
Issued: December 23, 2014
Inventor(s): McKinney Anthony A. & Tollefson Gary D. & Soltero Richard & Dunzo Thea Elise
Assignee(s): Orexigen Therapeutics, Inc.
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Patent expiration dates:
- February 2, 2030
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Sustained release formulation of naltrexone
Patent 9,107,837
Issued: August 18, 2015
Inventor(s): McKinney Anthony A. & Tollefson Gary D. & Soltero Richard & Dunzo Thea Elise
Assignee(s): Orexigen Therapeutics, Inc.
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Patent expiration dates:
- June 4, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Methods for administering weight loss medications
Patent 9,125,868
Issued: September 8, 2015
Inventor(s): McKinney Anthony A. & Tollefson Gary & Weber Eckard & Soltero Rick
Assignee(s): OREXIGEN THERAPEUTICS, INC.
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
Patent expiration dates:
- November 8, 2027
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
Methods of providing weight loss therapy in patients with major depression
Patent 9,248,123
Issued: February 2, 2016
Inventor(s): Dunayevich Eduardo & Tollefson Gary
Assignee(s): Orexigen Therapeutics, Inc.
Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
Patent expiration dates:
- January 13, 2032
  ✓
  Patent use: USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Methods of treating overweight and obesity
Patent 9,633,575
Issued: April 25, 2017
Inventor(s): Klassen Preston & Taylor Kristin
Assignee(s): Orexigen Therapeutics, Inc.
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Patent expiration dates:
- June 25, 2033
  ✓
  Patent use: FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

More about Contrave (bupropion / naltrexone)

Patient resources

Contrave drug information

Professional resources

Related treatment guides

Weight Loss (Obesity/Overweight)

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Guide to Weight Loss Drugs

Find out everything you need to know about weight loss drugs in our prescription weight loss drug guide.

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

6.6 / 10

1,988 Reviews

Images

Pill NB-890 is Contrave bupropion hydrochloride 90 mg / naltrexone hydrochloride 8 mg — Contrave bupropion hydrochloride 90 mg / naltrexone hydrochloride 8 mg (NB-890)